CRVS stock forecast
Our latest prediction for Corvus Pharmaceuticals, Inc.'s stock price was made on the Nov. 13, 2019 when the stock price was at 2.93$.
In the short term (2weeks), CRVS's stock price should outperform the market by 7.63%. During that period the price should oscillate between -9.56% and +19.74%.
In the medium term (3months), CRVS's stock price should outperform the market by 5.28%. During that period the price should oscillate between -19.66% and +43.52%.Get email alerts
About Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of oncology therapies. The company focuses on disabling cancer's ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment and by blocking its production by tumors. Its product pipeline includes Adenosine A2A Receptor Antagonist CPI-444, Adenosine Production Inhibitor Anti-CD73, Adenosine A2B Receptor Antagonist, ITK Inhibitor, and Myeloid Cell Suppression. The company was founded by Richard A. Miller, Peter A. Thompson, and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -1.57$ per share.
The book value per share is 4.36$
Three months stock forecastNov. 13, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|